Mount Sinai Health System
Search
Profile image of Christopher Sturgeon

    Christopher Sturgeon, PhD

    Education

    BSc(H), Carleton University

    PhD, University of British Columbia

    Postdoc, University of Toronto

    Awards

    2016

    Joanne Levy Award

    American Society of Hematology

    2016

    Scholar Award

    American Society of Hematology

    2007

    McEwen/McMurrich Regenerative Medicine Postdoctoral Fellowship

    McEwen Centre for Regenerative Medicine

    2005

    Roman M. Babicki Scholarship

    University of British Columbia

    2003

    NSERC PGS-B Scholarship

    NSERC

    2001

    NSERC PGA-A Scholarship

    NSERC

    Research

    The directed differentiation of human pluripotent stem cells (hPSC) towards the hematopoietic lineages would be an invaluable tool for regenerative medicine, providing cells for both transplantation and in vitro analysis. As the PSC system has been shown to recapitulate developmental events in vitro, it is also a powerful model system for developmental biology, being the only method to-date that allows interrogation of the cellular and molecular mechanisms that regulate human development. Furthermore, the recent technological advancement to generate induced pluripotent stem cells offers the potential to model not only development, but also disease in a dish.

    Current efforts to generate an hPSC-derived hematopoietic stem cell (HSC) are plagued by an inability to accurately discriminate between progenitors of the primitive and definitive hematopoietic programs, as there is no anatomical separation between the two in vitro. Briefly, very early in embryonic development the primitive hematopoietic program gives rise to a subset of lineages, including unique erythroblasts with high oxygen-affinity hemoglobin to promote embryonic survival, but no T cells or hematopoietic stem cells. This program is transient, and is shut down prior to the intra-embryonic emergence of the definitive hematopoietic program, which generates the full spectrum of hematopoietic lineages, including T cells and the hematopoietic stem cell. Both programs appear to progress in a similar fashion, passing through a mesodermal precursor and then subsequent hemogenic endothelium. However, as only the definitive program gives rise to a bona fide HSC, understanding the mechanism(s) that control specification of this program are essential to achieving this goal.

    The focus of my lab is to elucidate the signaling pathways governing the specification of both hematopoietic programs using hPSC directed differentiation. Through this we aim to better understand the transcriptional and epigenetic regulation that controls HSC development, and identify method(s) to specify a transplantable HSC in the dish. Work in my laboratory is focused on three main objectives:

    Understanding human primitive and definitive hematopoietic development

    Understanding the endothelial-to-hematopoietic transition in hemogenic endothelium, ultimately giving rise to an HSC

    Modeling hematopoietic disease with iPSC

    Please visit www.sturgeonlab.com for more information